Pro-Dex Inc (PDEX) — Titan Protect Analysis

PDEX

Pro-Dex Inc

Healthcare · ·

$65.21

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$215M

Total market value of the company

Trailing P/E

18.54

Reasonably valued

Forward P/E

32.67

Based on estimated future earnings — lower means cheaper

Rev Growth

+14.6%

Year-over-year revenue change

Profit Margin

16.1%

How much profit the company keeps from each dollar of revenue

ROE

29.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$70.00

+7% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Pro-Dex Inc

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its product

https://www.pro-dex.com

Country: United States Employees: 179 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.209

Excellent risk-adjusted returns

Kelly Fraction

0.0947

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.299

Returns exceed worst-case losses — strong risk profile

Annual Return

84.9%

Historical annualised return based on price data

Max Drawdown

-65.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

127

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.11

Very low correlation to market moves

52W High

$68.99

5% below the year high

52W Low

$23.47

178% above the year low

Avg Volume

29,787

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$3.63

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

44.63

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

27.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

15.5%

Profit from core operations before interest and tax

Free Cash Flow

$5M

Positive — the business generates more cash than it spends

Revenue (TTM)

$75M

Total revenue over the last 12 months

Net Income

$12M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$70.00

Target Median

$70.00

Target Low

$70.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go